The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.

Autor:	Chambers HF; University of California, San Francisco, San Francisco General Hospital., Cross HR; Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina., Evans SR; Center for Biostatistics in AIDS Research and Department of Biostatistics, Harvard University, Boston, Massachusetts., Kreiswirth BN; Public Health Research Institute Tuberculosis Center, New Jersey Medical School-Rutgers University, Newark; and., Fowler VG Jr; Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.; Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2017 Mar 15; Vol. 64 (suppl_1), pp. S3-S7.
DOI:	10.1093/cid/ciw824
Abstrakt:	The Antibacterial Resistance Leadership Group (ARLG), with funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, was created in June 2013. Its mission is to develop, prioritize, and implement a clinical research agenda that addresses the public health threat of antibacterial resistance. This article reports on the progress that the ARLG has made to date in fulfilling its mission. Since inception, the ARLG has received and reviewed >70 study proposals, initiated >30 studies, executed >300 agreements, included data from >7000 subjects, published >45 manuscripts, and provided opportunities for 26 mentees. Despite this substantial progress, there remains significant work to be accomplished. This article also describes the considerable challenges that lie ahead. (© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu